Bio-Techne (TECH) Stock Price & Analysis

TECH$72.78-0.04 -0.06%
BiotechnologyLarge CapHigh Quality
Compare
Market cap$11.43BEnterprise value$11.45BRevenue (TTM)$1.22BMarket positionTop 25%

Score

52
Neutral
Value
29
Quality
78
Growth
48

AI Analysis

Snapshot

Bio-Techne scores 52/100, but the multiple is asking a lot (P/E 62.2). Under the hood: P/E 62.2.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

29
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

48
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

78
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Bio-Techne Corporation (TECH) last printed $72.78. Equity value is $11.43B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2017201820192020202120222023202420252026
$563M$642.99M$714.01M$738.69M$931.03M$1.11B$1.14B$1.16B$1.22B$1.22B

About

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne (TECH) Stock Price & Analysis

TECH price $72.78 -0.04 -0.06%

Ticker
TECH
Price
$72.78
Change
-0.04 -0.06%
Market cap
$11.43B
Forward P/E
34.35
Dividend yield
0.44%
Beta
1.27
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
52
Value
29
Quality
78
Growth
48

Stocklytics score rationale: value 29, quality 78, growth 48.

AI Score 70. Bio-Techne Corporation has a strong gross profit margin of approximately 65.8% and a solid net profit margin of about 14.97%, indicating good profitability. However, its high price-to-earnings ratio of around 62.1 suggests that the stock may be overvalued, despite a reasonable growth outlook reflected in its price-to-earnings growth ratio of 0.40

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener